Key points from article :
OptiBiotix Health plc, a UK-based life sciences company focused on microbiome-targeted products for weight management, cholesterol, diabetes, and skin care, has released its full-year results for 2023. Published without a lead scientific author in a formal journal, the report details commercial highlights and new scientific findings relevant to popular health and nutrition audiences.
In 2023, OptiBiotix grew revenues by 41% to £644,000, driven by increasing sales of its flagship products SlimBiome® and LeanBiome®, with notable deals including Holland & Barrett and Walmart suppliers. The company also cut administrative expenses by about 30%, helping to improve its financial stability. It expanded into new markets, signing distribution and manufacturing deals in Asia, Australia, and India—including a significant licensing agreement with Tata Chemicals.
A key scientific highlight was a third human study on SlimBiome® submitted by Roehampton University. It showed the product significantly improved appetite and hunger regulation, without side effects, supporting its role in non-invasive weight loss solutions.
Looking ahead, CEO Stephen O’Hara emphasized continued momentum in early 2024 with major sales orders and new partnerships. With a strong balance sheet (~£9.4 million), no debt, and increasing global traction, the company is positioning itself as a leading player in the growing field of gut health and microbiome modulation.
